BIOMAT Database Logo BIOMAT Database Logo

[A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer]. 1989

V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev

Sucralfate (55 patients), cimetidine (25 patients), ranitidine (30 patients), antacids and cholinolytics (32 patients) were studied and compared in open clinical trials for the efficacy in the treatment of ulcer disease of the stomach and duodenum. During 5 weeks, ulcers completely healed in 100% of the patients given sucralfate (in 94.5% for 4 weeks), in 90% of the patients treated with ranitidine, in 84% on cimetidine, and in 78% of the patients undergoing treatment with antacids and cholinolytics.

UI MeSH Term Description Entries
D006993 Hypnotics and Sedatives Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. Hypnotic,Sedative,Sedative and Hypnotic,Sedatives,Hypnotic Effect,Hypnotic Effects,Hypnotics,Sedative Effect,Sedative Effects,Sedatives and Hypnotics,Effect, Hypnotic,Effect, Sedative,Effects, Hypnotic,Effects, Sedative,Hypnotic and Sedative
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010437 Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastroduodenal Ulcer,Marginal Ulcer,Gastroduodenal Ulcers,Marginal Ulcers,Peptic Ulcers,Ulcer, Gastroduodenal,Ulcer, Marginal,Ulcer, Peptic,Ulcers, Gastroduodenal,Ulcers, Marginal,Ulcers, Peptic
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Antacids and muscarinic and histamine H2 receptor blockaders in the treatment of peptic ulcer].
January 1987, Klinicheskaia meditsina,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Mechanism of action and therapeutic effectiveness of histamine H2 receptor blockaders in peptic ulcer].
February 1985, Vrachebnoe delo,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Action of histamine H2 receptor blockaders on gastric motor function in duodenal peptic ulcer].
June 1984, Klinicheskaia meditsina,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Treatment of recurrent ulcer with histamine-H2 blockaders].
January 1979, G.E.N,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.
November 1992, Drugs,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Effect of M-cholinolytics and histamine H2 receptor blockaders on the acid-peptide factor in patients with peptic ulcer].
October 1987, Klinicheskaia meditsina,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Comparative evaluation of methods of treating peptic ulcer].
September 1984, Khirurgiia,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical effects and problems; histamine H2 receptor blockaders].
January 1988, Nihon rinsho. Japanese journal of clinical medicine,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Histamine and H2 receptor blockaders].
September 1977, Therapie der Gegenwart,
V T Ivashkin, and E I Tkachenko, and V B Grinevich, and V K Sultanov, and S A Inozemtsev
[Long-term treatment of peptic ulcer with histamine H2 receptor blockaders: results of their use and new problems].
October 1991, Klinicheskaia meditsina,
Copied contents to your clipboard!